#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
Click to read this study in The Lancet Oncology.
Tag: ER-positive breast cancer
#VisualAbstract: Adjuvant ibandronate does not improve survival in postmenopausal patients with ER⁺ breast cancer
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer
Click to read this study in The Lancet Oncology.
#VisualAbstract: Metformin does not improve survival in patients with high-risk, nonmetastatic breast cancer
Click to read this study in JAMA.
#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression
Click to read this study in The Lancet Oncology.
Tamoxifen decreases recurrence rates at 25 years in lymph node-negative estrogen-receptor-positive and Erb-B2 Receptor Tyrosine Kinase 2-negative breast cancer
1. Tamoxifen reduced the long-term risk of breast cancer metastasis or recurrence and improved survival, especially in large, low-grade progesterone ...
#VisualAbstract: Early discontinuation of endocrine therapy may increase risk of breast cancer recurrence in premenopausal women
Click to read the study in Clinical Cancer Research.
#VisualAbstract: Endocrine therapy plus oral S-1 improves invasive disease-free survival in patients with ER⁺ breast cancer
Click to read the study in The Lancet Oncology.